Description
GANfort® (Allergan, Inc., Irvine, CA, USA), a fixed combination of bimatoprost 0.03% and timolol 0.5% (BTFC)–, is indicated for reduction of IOP in patients with POAG or ocular hypertension (OHT) who are insufficiently responsive to monotherapy.
